Employees: 67
Size Hyundai Bioscience (048410.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $424M, the 384th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩6,050 on 18 Nov 2026.
Performance Over six months the shares fell 50.2%, against -20.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 78.0% over the last twelve months (peer median +3.4%); the operating margin is -580.2% (peer median -3.3%).
Valuation It trades at 164.0× enterprise value to sales against a peer median of 3.0× (2nd most expensive of 19).
Capital Return on invested capital runs 24.8 points below its cost of capital (8.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩3.32B | ₩3.52B | ₩15.1B | ₩9.48B | ₩7.85B |
| Revenue growth | — | -77% | +59% | +21% | — |
| Gross profit | -₩1.00B | -₩1.03B | ₩11.2B | ₩3.92B | ₩1.95B |
| EBITDA | -₩17.8B | -₩16.9B | ₩1.47B | -₩8.37B | -₩24.5B |
| Net income | -₩26.5B | -₩22.1B | -₩6.93B | -₩14.5B | -₩15.8B |
| Free cash flow | -₩17.7B | -₩18.6B | ₩1.65B | -₩6.84B | -₩17.6B |
| Capital expenditure | ₩1.01B | ₩20.2B | ₩2.17B | ₩588M | ₩1.54B |
| Total debt | ₩22.8B | ₩17.8B | ₩26.6B | ₩5.55B | ₩6.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 048410.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.6% | -13.0% | 7th highest of 21 |
| 6-month return | -50.2% | -20.8% | 2nd lowest of 21 |
| Distance from 52-week high | -71.9% | -47.7% | 3rd lowest of 21 |
| Revenue growth (TTM) | +78.0% | +3.4% | 3rd highest of 19 |
| Operating margin | -580.2% | -3.3% | 3rd lowest of 19 |
| EV / Sales | 164.0× | 3.0× | 2nd most expensive of 19 |
| ROIC minus cost of capital | -24.8 pp | -7.0 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | 2.2× | 5.4% | +15.3% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 0.2× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 0.7× | -15.4% | +7.2% |
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | 208.3× | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | 6.2× | n/a | n/a |
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | 1.2× | 10.6% | +1.4% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | 7.1× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 3.2× | 24.4% | +8.0% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | 2.2× | 1.4% | -1.3% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 2.9× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 3.4× | -0.2% | +14.5% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 1.1× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 2.9× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | 119.7× | n/a | n/a |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | 10.6× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | 2.1× | -5.6% | -5.6% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | 4.2× | n/a | n/a |
| Rezolute RZLT | United States | $411M | +32% | n/a | n/a | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $410M | -49% | -88% | -676% | 4.7× | n/a | n/a |